Clinical Research Directory
Browse clinical research sites, groups, and studies.
Maintenance Venetoclax in AML Fit Patients
Sponsor: Sohag University
Summary
this study will explore the efficacy of maintenance SC cytarabine + venetoclax therapy as regard disease free survival (DFS) in AML fit patients who achieved CR after highly aggressive chemotherapy as bridge for BMT or if BMT will be delayed or canceled due to any other reason.
Official title: Maintenance Venetoclax Based Therapy Post Complete Remission in AML Fit Patients
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2025-09-01
Completion Date
2027-09-01
Last Updated
2025-11-24
Healthy Volunteers
No
Conditions
Interventions
SC cytarabine +Venetoclax
SC Cytarabine (20 mg) administrated on days 1-7 ,,Venetoclax (100 mg ) administrated on days 1-7,,Voriconazole 200 mg 1x2 administrated on days , Best supportive care as needed . Up to 12 cycles or until patients undergo bone marrow transplantation
Locations (2)
Sohag university hospital
Sohag, Egypt
Sohag university
Sohag, Egypt